Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic Hepatit

StephenW

Am J Gastroenterol. 2011 Aug 9. doi: 10.1038/ajg.2011.253. [Epub ahead of
print]

Quantitative Hepatitis B Surface Antigen Levels in Patients With Chronic
Hepatitis B After 2 Years of Entecavir Treatment.

Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF.

Source

Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong Special Administrative Region (SAR), China.

Abstract

OBJECTIVES:

The role of quantitative hepatitis B surface antigen (HBsAg) levels in
patients receiving oral antiviral therapy is controversial. We aimed to
determine the HBsAg response in chronic hepatitis B patients treated with
entecavir 0.5 mg daily for 2 years.

METHODS:

A total of 166 patients were included. Liver biochemistry, hepatitis B
virus (HBV) serological markers, HBV DNA, and quantitative HBsAg levels
were performed at baseline, year 1, and year 2 after commencing entecavir.
Additional HBsAg levels were measured at 12 and 24 weeks in patients with
available sera.

RESULTS:

In all, 68 patients were hepatitis B e-antigen (HBeAg) positive. Age, HBV
DNA, and alanine aminotransferase (ALT) were significantly correlated with
HBsAg levels at baseline (r=-0.429, 0.607, and 0.254, respectively, all
P<0.05). The correlation with HBV DNA and ALT levels was reduced by
entecavir treatment, and was lost after 2 years of treatment. There was an
overall decline in HBsAg levels from baseline to year 1 to year 2 (3,377.4
vs. 2,316.5 vs. 1,903.0 IU/ml, respectively, P<0.001). However, at year
2, 102 patients (61%) had no significant changes (<0.5 log difference), 50
(30%) had significant decline (≥0.5 log decrease), whereas 14 (9%) had
significant increase (≥0.5 log increase). Of the patients, 151 (91%) had
undetectable HBV DNA; 25 (37%) underwent HBeAg seroconversion. Neither
HBsAg at baseline nor early decline at weeks 12 or 24 was predictive of
HBeAg seroconversion at 2 years.

CONCLUSIONS:

Despite HBV DNA suppression, the majority did not show significant decline
in HBsAg levels. Early decline of HBsAg levels at 12/24 weeks was not
associated with HBV DNA suppression or HBeAg seroconversion.Am J
Gastroenterol advance online publication, 9 August 2011;
doi:10.1038/ajg.2011.253.

PMID: 21826112 [PubMed - as supplied by publisher]



(6.合.彩).足球.篮球...各类投注开户下注

第一投注.现金网:招代理年薪10万以上:6668.cc

StephenW

谷歌翻译不是100％正确。仅作为参考使用。

上午胃肠病学杂志。 2011年8月9。作者：10.1038/ajg.2011.253。 [检索策略打印]

定量乙肝表面抗原水平与慢性患者乙型肝炎恩替卡韦治疗2年后。

杨赖CL，丰J，J，黄DK，元J，濑户WK，元朗MF。

来源

香港大学玛丽医院内科部，
香港特别行政区（SAR）中国。

摘要

目标：

定量乙肝表面抗原（HBsAg）的水平的作用患者接受口服抗病毒治疗是有争议的。我们的目的是确定治疗慢性乙型肝炎患者乙肝表面抗原的反应恩替卡韦0.5毫克，每日2年。

方法：

共有166名患者被纳入。肝功能，B型肝炎病毒（HBV）血清标志物，乙肝病毒DNA，并定量HBsAg水平基线，今年1，第2年后开始替卡韦。附加HBsAg水平在12和24周分别测定患者可用血清。

结果：

在所有68例患者乙肝e抗原（HBeAg）阳性。
年龄，HBVDNA和丙氨酸转氨酶（ALT）显着正相关，与乙肝表面抗原 在基准水平（R =- 0.429，0.607和0.254，分别，所有P <0.05）。
HBV DNA 和 ALT水平的相关性减少了恩替卡韦治疗，并失去了2年的治疗后。
基线HBsAg水平整体下降，从今年1到第2年（3,377.4- 2,316.​​5 - 1,903.0 IU /毫升，分别为P <0.001）。
然而，在第2年，102例患者（61％）没有显着变化（<0.5log的区别），50（30％）有显着下降（下降≥0.5日志），而14（9％）显着增加（≥0.5log增加）。
这些病患中，151（91％）检测不到乙肝病毒DNA，25（37％）例HBeAg血清转换。
无论是在基线也不早在12周或24周下降的乙肝表面抗原是预测2年的e抗原血清转换。

结论：

尽管HBV DNA抑制，多数人没有表现出显着下降HBsAg水平。 12/24周早期的HBsAg水平下降是不与HBV DNA抑制或HBeAg seroconversion.  Am J胃肠病学杂志提前在线出版，2011年8月9日;
作者：10.1038/ajg.2011.253。